Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, Zhu B, Edson-Heredia E, Carlier H, Lin CY, Goldblum O, Yosipovitch G. Kimball AB, et al. Among authors: nikai e. J Am Acad Dermatol. 2016 Dec;75(6):1156-1161. doi: 10.1016/j.jaad.2016.07.034. Epub 2016 Sep 27. J Am Acad Dermatol. 2016. PMID: 27692498 Clinical Trial.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Langley RGB, et al. Among authors: nikai e. Qual Life Res. 2020 Feb;29(2):369-380. doi: 10.1007/s11136-019-02296-5. Epub 2019 Oct 26. Qual Life Res. 2020. PMID: 31655974 Clinical Trial.
Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations.
Blauvelt A, Griffiths CEM, Lebwohl M, Mrowietz U, Puig L, Ball S, Zhang L, Edson-Heredia E, Warner M, Zhu B, Lin CY, Nikaï E, Dey D, Mallbris L, Reich K. Blauvelt A, et al. Among authors: nikai e. Br J Dermatol. 2017 Aug;177(2):587-590. doi: 10.1111/bjd.15463. Epub 2017 Jul 3. Br J Dermatol. 2017. PMID: 28301048 Clinical Trial. No abstract available.
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.
Strand V, Smolen JS, van Vollenhoven RF, Mease P, Burmester GR, Hiepe F, Khanna D, Nikaï E, Coteur G, Schiff M. Strand V, et al. Among authors: nikai e. Ann Rheum Dis. 2011 Jun;70(6):996-1002. doi: 10.1136/ard.2010.143586. Epub 2011 Mar 17. Ann Rheum Dis. 2011. PMID: 21415050 Free PMC article. Clinical Trial.
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A. Strand V, et al. Among authors: nikai e. Arthritis Res Ther. 2009;11(6):R170. doi: 10.1186/ar2859. Epub 2009 Nov 12. Arthritis Res Ther. 2009. PMID: 19909548 Free PMC article. Clinical Trial.
Updating the OMERACT filter: implications for patient-reported outcomes.
Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, Choy E, de Wit M, Guillemin F, Hewlett S, Kvien TK, Landewé RB, Leong AL, Lyddiatt A, March L, May J, Montie PL, Nikaï E, Richards P, Voshaar MM, Smeets W, Strand V, Tugwell P, Gossec L. Kirwan JR, et al. Among authors: nikai e. J Rheumatol. 2014 May;41(5):1011-5. doi: 10.3899/jrheum.131312. Epub 2014 Mar 1. J Rheumatol. 2014. PMID: 24584919
23 results